- Home
- BEAM vs XNDU Comparison
BEAM vs XNDU Comparison
Compare BEAM & XNDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEAM | XNDU |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | Canada |
| Employees | N/A | 264 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.6B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BEAM | XNDU |
|---|---|---|
| Price | $32.75 | $11.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $50.75 | $44.00 |
| AVG Volume (30 Days) | 2.6M | ★ 3.0M |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 33.33 | N/A |
| 52 Week Low | $15.60 | $6.97 |
| 52 Week High | $38.26 | $42.44 |
Technical Indicators
Market Signals| Indicator | BEAM | XNDU |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 41.59 |
| Support Level | $23.83 | $10.63 |
| Resistance Level | $35.18 | $14.54 |
| Average True Range (ATR) | 2.84 | 0.79 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 21.32 | 19.09 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
About XNDU Xanadu Quantum Technologies Limited Class B Subordinate Voting Shares
Xanadu Quantum Technologies Ltd specializes in designing photonic devices and the platforms around them, including the experimentation and development of quantum computers available on the cloud with supporting software, along with quantum simulators and other related products and offerings. Its products include: Aurora, PennyLane, Catalyst, Lightning, Catalyst and PennyLane Codebook. The company operates in industries such as automotive, aerospace, energy, materials, and semiconductor sectors.